RED HOT Contributors

 

Abbott wins CE Mark for next-gen Xience Sierra drug-eluting stent

0
Share

Abbott logoAbbott (NYSE:ABT) said today that it won CE Mark approval in the European Union for its next-generation drug-eluting stent, the Xience Sierra.

The everolimus-eluting coronary stent is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases, the Chicago-area healthcare giant said. If offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.

Get the full story at our sister site, Drug Delivery Business News.

About

We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast